# A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

> clinical trial · VERIFIED · 2026-06-26

Status: RECRUITING · Sponsor: Bristol-Myers Squibb · Condition: Non-Small Cell Lung Cancer (NSCLC)

- Company: Bristol-Myers Squibb
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07361510

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.